NCT06898424 is a NA clinical trial of Ketoflex 12/3 Diet in Alzheimer Type Dementia, sponsored by Prof. Lutfu Hanoglu, MD.

Who is sponsoring NCT06898424?

NCT06898424 is sponsored by Prof. Lutfu Hanoglu, MD.

What drugs are being tested in NCT06898424?

Interventions in NCT06898424: Ketoflex 12/3 Diet.

What condition does NCT06898424 study?

NCT06898424 studies Alzheimer Type Dementia, Alzheimer's Disease (AD).

Is NCT06898424 still recruiting?

NCT06898424 is currently completed. Last updated 24 March 2026.

Last reviewed 2026-03-24 · How we verify

NCT06898424

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression

Completed NA Last updated 24 March 2026

What this trial tests

NA trial testing Ketoflex 12/3 Diet in Alzheimer Type Dementia in 60 participants. Completed in 31 October 2024.

Timeline

1 March 2024

Primary endpoint
30 September 2024

31 October 2024

Quick facts

Lead sponsor	Prof. Lutfu Hanoglu, MD
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	60
Start date	1 March 2024
Primary completion	30 September 2024
Estimated completion	31 October 2024
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Ketoflex 12/3 Diet

Conditions studied

Alzheimer Type Dementia — all drugs for Alzheimer Type Dementia →
Alzheimer's Disease (AD) — all drugs for Alzheimer's Disease (AD) →

Sponsor

Prof. Lutfu Hanoglu, MD

Who can join

Adults 50 to 85, any sex, with Alzheimer Type Dementia or Alzheimer's Disease (AD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease. The study evaluates cognitive function, metabolic changes, and overall health outcomes in participants following the Ketoflex 12/3 dietary protocol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ketoflex 12/3 Diet

Trials testing the same drug.

NCT06892418 — Impact of Ketoflex 12/3 Diet on Parkinson's Disease Symptoms: A Clinical Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06898424 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prof. Lutfu Hanoglu, MD
Last refreshed: 24 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06898424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing